FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:1026-1028 March 5, 2009 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Haldar, P. Related Article by Nair, P.

Although the origin of the concept that eosinophils are critical to asthma pathobiology remains controversial, there is consensus that Paul Ehrlich first identified a bilobed nucleated cell as an "eosin"-ophil in 1879 on the basis of the cell's granular uptake of his newly discovered dye. These cells were soon found in airway tissues and "catarrh" (sputum) of patients with asthma. Over the years, eosinophils were identified as a prominent cell type in asthma, yet their role as either an "effector" or "innocent bystander" was not confirmed until the publication of articles by Nair et al.¹ and Haldar et al.² in . . . [Full Text of this Article]

Source Information

From the University of Pittsburgh, Pittsburgh.

This article has been cited by other articles:

• Zarogiannis, S., Gourgoulianis, K. I., Kostikas, K., Szczeklik, A., Gleich, G. J., Pavord, I. D., Wardlaw, A. J., Haldar, P., Nair, P., Hargreave, F. E., O'Byrne, P., Wenzel, S. E. (2009). Anti-Interleukin-5 Therapy and Severe Asthma. NEJM 360: 2576-2578 [Full Text]  
• Humbert, M. (2009). Biologics in severe difficult-to-treat asthma: find the right niche!. ERR 18: 51-53 [Full Text]